L. Flaherty

发表

Randomized Phase II Trial of Sorafenib with Temsirolimus or Tipifarnib in Untreated Metastatic Melanoma (S0438)

V. Sondak, J. Sosman, J. Kirkwood, 2012, Clinical Cancer Research.

Phase II trial of biochemotherapy with interferon α, dacarbazine, cisplatin and tamoxifen in metastatic melanoma: a Southwest Oncology Group trial

V. Sondak, J. Sosman, G. Weiss, 1999, Journal of Cancer Research and Clinical Oncology.

Targeted therapies: Improved outcomes for patients with metastatic melanoma

V. Sondak, L. Flaherty, 2011, Nature Reviews Clinical Oncology.

Final results of E2603: A double-blind, randomized phase III trial comparing carboplatin (C)/paclitaxel (P) with or without sorafenib (S) in metastatic melanoma.

K. Flaherty, J. Kirkwood, J. Wright, 2010 .

Phase II Trial of Recombinant Human Interleukin‐4 in Patients with Disseminated Malignant Melanoma: A Southwest Oncology Group Study

V. Sondak, J. Unger, J. Thompson, 1998, Journal of immunotherapy.

Phase I trial of recombinant macrophage colony-stimulating factor by rapid intravenous infusion in patients with cancer.

S. Martino, B. Redman, M. Simon, 1992, Journal of immunotherapy.

Phase II trial of recombinant human macrophage colony-stimulating factor in metastatic soft tissue sarcoma.

B. Redman, M. Zalupski, L. Baker, 1994, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.

Factors associated with breast cancer clinical trials participation and enrollment at a large academic medical center.

P. Philip, P. LoRusso, M. Simon, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190.

V. Sondak, J. Kirkwood, T. Smith, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase III Study of Adjuvant Ipilimumab (3 or 10 mg/kg) Versus High-Dose Interferon Alfa-2b for Resected High-Risk Melanoma: North American Intergroup E1609.

V. Sondak, J. Sosman, J. Kirkwood, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

New Options for the Adjuvant Treatment of Cutaneous Melanoma?

L. Flaherty, A. Weise, 2014, Current Oncology Reports.

Southwest Oncology Group S0008: a phase III trial of high-dose interferon Alfa-2b versus cisplatin, vinblastine, and dacarbazine, plus interleukin-2 and interferon in patients with high-risk melanoma--an intergroup study of cancer and leukemia Group B, Children's Oncology Group, Eastern Cooperative

V. Sondak, M. Atkins, B. Redman, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Use and abuse of statistics in evidence-based medicine.

V. Sondak, J. Kirkwood, M. Ernstoff, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Treatment of malignant melanoma with interleukin-2.

P. Philip, L. Flaherty, 1997, Seminars in oncology.

Phase II trial of sequential radiation and interleukin 2 in the treatment of patients with metastatic renal cell carcinoma.

G. Haas, B. Redman, J. Forman, 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

Adjuvant H igh-Dose B olus I nterleukin-2 f or P atients W ith High-Risk R enal C ell C arcinoma: A C ytokine W orking G roup Randomized T rial

R. Figlin, M. Atkins, B. Redman, 2003 .

Adjuvant therapy of melanoma: is pegylated interferon alfa-2b what we've been waiting for?

V. Sondak, L. Flaherty, 2008, The Lancet.

Phase I trial of Adozelesin using the treatment schedule of daily × 5 every 3 weeks

A. Wozniak, P. LoRusso, M. Zalupski, 1995, Investigational New Drugs.

A phase II trial of oral diethylstilbesterol as a second-line hormonal agent in advanced prostate cancer.

K. Pienta, B. Redman, M. Strawderman, 1998, Urology.

Surgical adjuvant active specific immunotherapy for patients with stage III melanoma: the final analysis of data from a phase III, randomized, double-blind, multicenter vaccinia melanoma oncolysate trial.

K. Bland, C. Balch, A. Bartolucci, 1998, Journal of the American College of Surgeons.

A phase III randomized, doúble‐blind, multiinstitutional trial of vaccinia melanoma oncolysate‐active specific immunotherapy for patients with stage II melanoma

K. Bland, C. Balch, A. Bartolucci, 1995, Cancer.

Outpatient biochemotherapy with interleukin-2 and interferon alfa-2b in patients with metastatic malignant melanoma: results of two phase II cytokine working group trials.

R. Fisher, J. Sosman, G. Weiss, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I Clinical Trial of 5-Fluoro-Pyrimidinone (5FP), an Oral Prodrug of 5-Fluorouracil (5FU)

A. Wozniak, A. Shields, P. LoRusso, 2002, Investigational New Drugs.

An Open–Label, Randomized, Multi–Center Study Comparing the Sequence of High Dose Aldesleukin (Interleukin–2) and Ipilimumab (Yervoy) in Patients with Metastatic Melanoma

S. Patel, G. Daniels, W. Sharfman, 2021, Oncoimmunology.

SWOG S0215: a phase II study of docetaxel and vinorelbine plus filgrastim with weekly trastuzumab for HER2-positive, stage IV breast cancer

G. Hortobagyi, R. Livingston, W. Barlow, 2011, Breast Cancer Research and Treatment.

CNS metastases as a site of progression on SWOG intergroup study S0008: A phase III trial of high-dose interferon alpha-2b versus cisplatin, vinblastine, DTIC plus IL-2 (BCT) versus high-dose interferon (HDI) in patients with high-risk melanoma.

V. Sondak, M. Atkins, J. Kirkwood, 2012 .

Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial coordinated by the Eastern Cooperative Oncology Grou

V. Sondak, M. Atkins, J. Sosman, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II clinical trial using anti-CD3 × anti-HER2 bispecific antibody armed activated T cells (HER2 BATs) consolidation therapy for HER2 negative (0–2+) metastatic breast cancer

M. Simon, A. Thakur, A. Deol, 2021, Journal for ImmunoTherapy of Cancer.

Scintigraphic findings in patients with shoulder pain caused by interleukin-2.

J. Muz, M. Valdivieso, L. Flaherty, 1990, AJR. American journal of roentgenology.

A phase III randomized study of adjuvant ipilimumab (3 or 10 mg/kg) versus high-dose interferon alfa-2b for resected high-risk melanoma (U.S. Intergroup E1609): Preliminary safety and efficacy of the ipilimumab arms.

V. Sondak, J. Sosman, J. Kirkwood, 2017 .

S0221: Comparison of two schedules of paclitaxel as adjuvant therapy for breast cancer.

G. Hortobagyi, C. Isaacs, R. Livingston, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II trial of paclitaxel and carboplatin in the treatment of advanced urothelial carcinoma.

B. Redman, D. Smith, W. Du, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

United States Intergroup E1609: A phase III randomized study of adjuvant ipilimumab (3 or 10 mg/kg) versus high-dose interferon-α2b for resected high-risk melanoma.

V. Sondak, J. Sosman, J. Kirkwood, 2019, Journal of Clinical Oncology.

Phase II Southwest Oncology Group study of docetaxel and vinorelbine plus filgrastim with weekly trastuzumab for HER2-positive, stage IV breast cancer

G. Hortobagyi, R. Livingston, W. Barlow, 2008 .

A phase II study of 17-allylamino-17-demethoxygeldanamycin in metastatic or locally advanced, unresectable breast cancer

P. LoRusso, J. Abrams, M. Simon, 2012, Breast Cancer Research and Treatment.

A Phase II Trial of Imatinib Mesylate in Merkel Cell Carcinoma (Neuroendocrine Carcinoma of the Skin): A Southwest Oncology Group Study (S0331)

V. Sondak, M. Heinrich, J. Moon, 2010, American journal of clinical oncology.

Cancer Site and Adverse Events Induced by Immune Checkpoint Inhibitors: A Retrospective Analysis of Real-life Experience at a Single Institution

A. Wozniak, S. Gadgeel, U. Vaishampayan, 2019, AntiCancer Research.

Oral etoposide in the treatment of hormone‐refractory prostate cancer

K. Pienta, B. Redman, M. Hussain, 1994, Cancer.

SWOG 8825: melphalan GM-CSF: a phase I study.

B. Redman, D. Alberts, E. Poplin, 1992, Gynecologic oncology.

A phase I trial of recombinant interleukin-2 combined with recombinant interferon-gamma in patients with cancer.

S. Martino, B. Redman, A. Al-Katib, 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase III trial of high-dose interferon alpha-2b versus cisplatin, vinblastine, DTIC plus IL-2 and interferon in patients with high-risk melanoma (SWOG S0008): An intergroup study of CALGB, COG, ECOG, and SWOG.

V. Sondak, M. Atkins, B. Redman, 2012 .

Biochemotherapy for melanoma

P. Philip, L. Flaherty, 2000, Seminars in oncology.

A phase II study of dacarbazine and cisplatin in combination with outpatient administered interleukin‐2 in metastatic malignant melanoma

S. Martino, B. Redman, R. Gonzalez, 1993, Cancer.

Phase II trial of pegylated interferon (Peg-Intron) and thalidomide (Thal) in pretreated metastatic malignant melanoma

U. Vaishampayan, L. Heilbrun, L. Flaherty, 2005 .

Alteration of dacarbazine pharmacokinetics after interleukin-2 administration in melanoma patients

L. Baker, M. Valdivieso, L. Flaherty, 2004, Cancer Chemotherapy and Pharmacology.

Acute pancreatitis associated with high-dose interleukin-2 immunotherapy for malignant melanoma.

B. Redman, W. Samlowski, J. Ward, 1990, The Western journal of medicine.

Phase 2 trial of combination thalidomide plus temozolomide in patients with metastatic malignant melanoma: Southwest Oncology Group S0508

V. Sondak, J. Sosman, J. Moon, 2010, Cancer.

A phase II evaluation of all-trans-retinoic acid plus interferon alfa-2a in stage IV melanoma: a Southwest Oncology Group study.

V. Sondak, D. Gandara, S. Balcerzak, 1999, The cancer journal from Scientific American.

Metastatic melanoma from intraocular primary tumors: the Southwest Oncology Group experience in phase II advanced melanoma clinical trials.

V. Sondak, J. Unger, L. Flaherty, 1998, American journal of clinical oncology.

Temozolomide and whole brain irradiation in melanoma metastatic to the brain: a phase II trial of the Cytokine Working Group

J. Sosman, G. Weiss, M. Ernstoff, 2002, Journal of Cancer Research and Clinical Oncology.

Phase II evaluation of paclitaxel, α‐interferon, and cis‐retinoic acid in advanced renal cell carcinoma

W. Du, U. Vaishampayan, M. Hussain, 2001 .

Chronic Oral Administration of CI-994: A Phase I Study

A. Wozniak, P. LoRusso, M. Meyer, 2004, Investigational New Drugs.

Randomized trial of adjuvant human interferon gamma versus observation in high-risk cutaneous melanoma: a Southwest Oncology Group study.

V. Sondak, J. Doroshow, C. Taylor, 1995, Journal of the National Cancer Institute.

Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working group randomized trial.

R. Figlin, M. Atkins, B. Redman, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Weekly 1‐hour infusion of paclitaxel

B. Redman, O. Kucuk, M. Hussain, 2000, Cancer.

Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma.

M. Atkins, J. Sosman, J. Kirkwood, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II evaluation of oral estramustine and oral etoposide in hormone-refractory adenocarcinoma of the prostate.

B. Redman, M. Hussain, L. Flaherty, 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase II evaluation of oral tamoxifen and intermittent intravenous vinblastine in hormone-refractory adenocarcinoma of the prostate.

K. Pienta, B. Redman, L. Flaherty, 1996, American journal of clinical oncology.

A multi-center phase II study of high dose IL-2 (HD IL-2) sequenced with vemurafenib in patients with BRAF-V600E mutation positive advanced melanoma.

M. Ernstoff, M. Milhem, Joseph I. Clark, 2015 .

Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b study.

A. Ribas, I. Puzanov, A. Daud, 2014, The Lancet. Oncology.

Molecular profiling of melanoma brain metastases compared to primary cutaneous melanoma and to extracranial metastases

M. Atkins, G. Gibney, B. Eisenberg, 2020, Oncotarget.

The addition of tamoxifen to dacarbazine and cisplatin in metastatic malignant melanoma. A phase II trial of the Southwest Oncology Group, (SWOG-8921).

V. Sondak, M. Walker, L. Flaherty, 1996, American journal of clinical oncology.

Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: impact of HLA class I antigen expression on outcome.

V. Sondak, J. Sosman, J. Unger, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A study of paclitaxel, carboplatin, and bortezomib in the treatment of metastatic malignant melanoma

G. Linette, C. Erlichman, V. Suman, 2010, Cancer.

Implications of microscopic satellites of the primary and extracapsular lymph node spread in patients with high-risk melanoma: pathologic corollary of Eastern Cooperative Oncology Group Trial E1690.

J. Kirkwood, U. Rao, J. Richards, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase III trial of carboplatin and paclitaxel with or without sorafenib in metastatic melanoma.

K. Flaherty, M. Atkins, J. Kirkwood, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Single-Arm, Open-Label, Expanded Access Study of Vemurafenib in Patients With Metastatic Melanoma in the United States

G. Linette, J. Hainsworth, K. Flaherty, 2014, Cancer journal.

A phase 2 trial of complete resection for stage IV melanoma

V. Sondak, B. Redman, J. Sosman, 2011, Cancer.

SWOG S0221: a phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancer.

G. Hortobagyi, C. Isaacs, R. Livingston, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II trial of pegylated interferon and thalidomide in malignant metastatic melanoma

U. Vaishampayan, L. Heilbrun, L. Flaherty, 2007, Anti-cancer drugs.

Randomized phase III trial of high-dose interferon alfa-2b (HDI) for 4 weeks induction only in patients with intermediate- and high-risk melanoma (Intergroup trial E 1697) .

J. Kirkwood, M. Smylie, R. Kefford, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: overall results of a randomized trial of the Southwest Oncology Group.

V. Sondak, B. Redman, J. Sosman, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Increased survival of patients treated with a vaccinia melanoma oncolysate vaccine: second interim analysis of data from a phase III, multi-institutional trial.

K. Bland, C. Balch, A. Bartolucci, 1997, Annals of surgery.

Treatment of metastatic malignant melanoma

L. Flaherty, E. Atallah, 2005, Current treatment options in oncology.

A multi-center phase II study of high dose interleukin-2 sequenced with vemurafenib in patients with BRAF-V600 mutation positive metastatic melanoma

M. Ernstoff, B. Taback, J. Lutzky, 2018, Journal of Immunotherapy for Cancer.

Phase III Randomized Study of 4 Weeks of High-Dose Interferon-α-2b in Stage T2bNO, T3a-bNO, T4a-bNO, and T1-4N1a-2a (microscopic) Melanoma: A Trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group (E1697).

V. Sondak, M. Atkins, J. Sosman, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

High frequency of brain metastases after adjuvant therapy for high‐risk melanoma

V. Sondak, M. Atkins, J. Kirkwood, 2017, Cancer medicine.

Biochemotherapy for melanoma.

P. Philip, S. Gadgeel, L. Flaherty, 2002, Current oncology reports.

Phase II study of carmustine, dacarbazine, cisplatin, and tamoxifen in advanced melanoma: a Southwest Oncology Group study.

V. Sondak, J. Sosman, G. Weiss, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adjuvant Vaccine Immunotherapy of Resected, Clinically Node-Negative Melanoma: Long-term Outcome and Impact of HLA Class I Antigen Expression on Overall Survival

V. Sondak, J. Sosman, A. Ribas, 2014, Cancer Immunology Research.

Issue 3: Treatment of Melanoma in Special Circumstances

L. Flaherty, 2007 .

Immune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of immunosuppressants and association with outcome: ECOG-ACRIN E1609 study analysis

V. Sondak, J. Sosman, J. Kirkwood, 2021, Journal for ImmunoTherapy of Cancer.

Gender and other survival predictors in patients with metastatic melanoma on Southwest Oncology Group trials

V. Sondak, J. Unger, K. Albain, 2001 .

Sequential dacarbazine/cisplatin and interleukin-2 in metastatic melanoma: immunological effects of therapy.

B. Redman, A. Nakeff, T. Chou, 1991, Journal of immunotherapy.

A phase I‐II study of dacarbazine in combination with outpatient interleukin‐2 in metastatic malignant melanoma

S. Martino, B. Redman, L. Heilbrun, 1990, Cancer.

Three phase II cytokine working group trials of gp100 (210M) peptide plus high-dose interleukin-2 in patients with HLA-A2-positive advanced melanoma.

B. LaFleur, M. Atkins, J. Sosman, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Rationale for intergroup trial E-3695 comparing concurrent biochemotherapy with cisplatin, vinblastine, and DTIC alone in patients with metastatic melanoma.

L. Flaherty, 2000, The cancer journal from Scientific American.

A Cytokine Working Group (CWG) 3-arm phase II trial of gp100 (209–2M) peptide + high dose (HD) Interleukin-2 (IL-2) in HLA-A2+ (A2+) advanced melanoma patients (pts)

Jeffrey W. Clark, M. Atkins, J. Sosman, 2005 .

Risk assessment in localized primary cutaneous melanoma: a Southwest Oncology Group study evaluating nine factors and a test of the Clark logistic regression prediction model.

V. Sondak, J. Unger, L. Flaherty, 2002, American journal of clinical pathology.

Comparison of patient characteristics and outcome between a single-institution phase II trial and a cooperative-group phase II trial with identical eligibility in metastatic melanoma.

V. Sondak, J. Unger, P Y Liu, 1997, American journal of clinical oncology.

Evaluation of interferon alpha‐2B and thalidomide in patients with disseminated malignant melanoma, phase 2, SWOG 0026

V. Sondak, J. Moon, L. Hutchins, 2007, Cancer.

Significant impact of HLA class I allele expression on outcome in melanoma patients treated with an allogeneic melanoma cell lysate vaccine. Final analysis of SWOG-9035

V. Sondak, J. Sosman, J. Unger, 2004 .

Significant impact of HLA class I allele expression on outcome in melanoma patients treated with an allogeneic melanoma cell lysate vaccine. Final analysis of SWOG-9035.

V. Sondak, J. Sosman, J. Unger, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II study of deoxydoxorubicin in previously untreated metastatic breast cancer

B. Redman, M. Simon, M. Valdivieso, 1990, Breast Cancer Research and Treatment.

A phase II trial of piroxantrone in disseminated malignant melanoma

V. Sondak, J. Sosman, J. Thompson, 2007, Investigational New Drugs.

Inhibition of prostate cancer growth by estramustine and etoposide

K. Pienta, B. Redman, M. Hussain, 1995, The Journal of urology.

Phase I clinical trial of pyrazoloacridine NSC366140 (PD115934).

P. Lorusso, L. Baker, L. Heilbrun, 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

Phase II chemoprevention trial of oral fenretinide in patients at risk for adenocarcinoma of the prostate.

F. Zwas, L. Flaherty, P. Esper, 1997, American journal of clinical oncology.

A Phase II Trial of Pyrazine Diazohydroxide in Patients with Disseminated Malignant Melanoma and no Prior Chemotherapy – Southwest Oncology Group Study

V. Sondak, J. Unger, E. Kraut, 2002, Investigational New Drugs.

5‐fluorouracil, etoposide, and cisplatin in the management of metastatic non‐small cell lung cancer

S. Martino, B. Redman, A. Wozniak, 1991, Cancer.

Phase II trial of recombinant interleukin-1β in patients with metastatic renal cell carcinoma

B. Redman, T. Chou, L. Flaherty, 1994 .

Immune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of hormone replacement and immunosuppressants, and association with outcome: E1609 study analysis.

V. Sondak, J. Kirkwood, F. Hodi, 2020 .

Phase 2 study of RO4929097, a gamma‐secretase inhibitor, in metastatic melanoma: SWOG 0933

V. Sondak, B. Redman, A. Ribas, 2015, Cancer.

Phase II trial of interferon and thalidomide in metastatic renal cell carcinoma

A. Shields, U. Vaishampayan, L. Heilbrun, 2006, Investigational New Drugs.

A Phase II Study of Docetaxel, Doxorubicin, and Infusional 5-Fluorouracil in the Treatment of Patients With Locally Advanced Breast Cancer

P. Philip, P. LoRusso, J. Abrams, 2006, American journal of clinical oncology.

Dacarbazine and outpatient interleukin-2 in treatment of metastatic malignant melanoma: phase II Southwest Oncology Group trial.

V. Sondak, S. Balcerzak, L. Flaherty, 1992, Journal of the National Cancer Institute.

A phase II trial of piroxantrone in disseminated malignant melanoma. A Southwest Oncology Group study.

V. Sondak, J. Sosman, J. Thompson, 1995, Investigational new drugs.

Difluorodeoxycytidine (dFdC) — gemcitabine: A phase I study

B. Redman, L. Baker, M. Valdivieso, 1992, Investigational New Drugs.

Phase II Trial of CI-980 in Patients with Disseminated Malignant Melanoma and no Prior Chemotherapy – A Southwest Oncology Group Study

V. Sondak, J. Unger, W. Samlowski, 2004, Investigational New Drugs.

SWOG S0826: A phase II trial of SCH 727965 (NSC 747135) in patients with stage IV melanoma.

V. Sondak, A. Ribas, J. Moon, 2012 .

Erratum: Weekly 1-hour infusion of paclitaxel: Clinical feasibility and efficacy in patients with hormone-refractory prostate carcinoma (Cancer (2000) 89 (431-6))

B. Redman, O. Kucuk, L. Flaherty, 2000 .

Evaluation of merbarone (NSC 336628) in disseminated malignant melanoma

V. Sondak, E. Kraut, M. Slavik, 2004, Investigational New Drugs.

Phase II evaluation of paclitaxel, alpha-interferon, and cis-retinoic acid in advanced renal cell carcinoma.

W. Du, U. Vaishampayan, M. Hussain, 2001, Cancer.

Secondary acute myelogenous leukemia following treatment with oral etoposide

M. Varterasian, L. Flaherty, K. Katato, 1996, American journal of hematology.

Phase II trial of CI-980 in patients with disseminated malignant melanoma and no prior chemotherapy

V. Sondak, J. Unger, W. Samlowski, 2001 .

ACCO: ASCO core curriculum outline.

J. V. Von Roenn, L. Deangelis, P. Harari, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized Phase II Trial of Sorafenib with Temsirolimus or Tipifarnib in Untreated Metastatic Melanoma (S0438)

V. Sondak, J. Sosman, J. Kirkwood, 2012, Clinical Cancer Research.

Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b study.

A. Ribas, I. Puzanov, A. Daud, 2014, The Lancet. Oncology.

A phase II study of rebeccamycin analog (NSC-655649) in metastatic renal cell cancer

P. LoRusso, U. Vaishampayan, M. Hussain, 2003, Investigational New Drugs.

Phase I Clinical Trial of Pyrazoloacridine N 5 C 366140 ( PD 115934 ) ’

P. LoRusso, L. Baker, L. Heilbrun, 2005 .